Press coverage about OncoSec Medical (NASDAQ:ONCS) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. OncoSec Medical earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.1721579136615 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of research firms recently issued reports on ONCS. Dawson James reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Thursday, July 6th. ValuEngine upgraded OncoSec Medical from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. Maxim Group set a $5.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a report on Saturday, June 3rd. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of OncoSec Medical in a report on Friday, June 2nd. Finally, Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a report on Friday, May 12th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. OncoSec Medical has a consensus rating of “Buy” and an average target price of $5.33.

OncoSec Medical (NASDAQ ONCS) traded up 6.413% on Friday, hitting $0.979. The company had a trading volume of 51,977 shares. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The stock’s 50-day moving average price is $1.00 and its 200 day moving average price is $1.14. The company’s market capitalization is $20.72 million.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings results on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. On average, analysts expect that OncoSec Medical will post ($1.02) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.